Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

Rhea-AI Summary

Profound Medical (NASDAQ:PROF), a commercial-stage medical device company specializing in incision-free tissue ablation therapies, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments. Investors can access the call through registration and listen to the live broadcast on the company's website.

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Second Quarter 2025 Results Conference Call Details:

Date: Thursday, August 14, 2025

Time: 4:30 p.m. ET

Live Call Registration: https://register-conf.media-server.com/register/BId85901c392a54415b6f548e3faded51e

The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO^® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO^® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve^® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve^® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

When will Profound Medical (PROF) release Q2 2025 earnings?

Profound Medical will release its Q2 2025 financial results after market close on Thursday, August 14, 2025.

What time is Profound Medical's Q2 2025 earnings conference call?

The earnings conference call is scheduled for 4:30 p.m. ET on Thursday, August 14, 2025.

How can investors access Profound Medical's Q2 2025 earnings call?

Investors can access the call through registration at the provided link and listen to the live broadcast on the company's website at www.profoundmedical.com under 'Webcasts' in the Investors section.

What does Profound Medical (PROF) company do?

Profound Medical is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.